RYR2 and plasma cell myeloma: By performing mutational analysis, we revealed that patients with high CAS had a higher mutational frequency of NBEA and FRAS1 and a lower mutational frequency of RYR2. NBEA has been certified as a novel tumor suppressor gene, and mutation of NBEA can cause poor outcomes in multiple myeloma (36).